Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 98

Sort by

Sort Order Select

Journal Articles

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Armin Ghobadi, Robert Baiocchi, Amer M. Beitinjaneh, Sridhar Chaganti, Sylvain Choquet, Daan Dierickx, Rajani Dinavahi, Xinyuan Duan, Laurence Gamelin, Kris Michael Mahadeo, Aditi Mehta, Sarah Nikiforow, Ran Reshef, Sandrine Roye, Jean-Claude Vedovato, Susan E Prockop

Blood (2024) 144 (Supplement 1): 70.

https://doi.org/10.1182/blood-2024-198159

Published: 2024

Journal Articles

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

H. Moses Murdock, Haesook T. Kim, Katie Maurer, Amar H. Kelkar, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Corey S. Cutler, John Koreth, Jerome Ritz, Joseph H. Antin, Vincent T. Ho, Sarah Nikiforow, Catherine J. Wu, Robert J. Soiffer

Blood (2024) 144 (Supplement 1): 3538.

https://doi.org/10.1182/blood-2024-204343

Published: 2024

Journal Articles

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Michela Ansuinelli, Haesook T. Kim, Carol G. Reynolds, Francesco Malfona, Shuntaro Ikegawa, Rakuyo Tamada, Roman M. Shapiro, Mahasweta Gooptu, Rizwan Romee, Sarah Nikiforow, John Koreth, Vincent T. Ho, Corey S. Cutler, Joseph H. Antin, Leslie Kean, Robert J. Soiffer, Jerome Ritz

Blood (2024) 144 (Supplement 1): 1041.

https://doi.org/10.1182/blood-2024-201835

Published: 2024

Journal Articles

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Blood (2024) 144 (Supplement 1): 149.

https://doi.org/10.1182/blood-2024-199890

Published: 2024

Journal Articles

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

Blood (2024) 144 (Supplement 1): 379.

https://doi.org/10.1182/blood-2024-200128

Published: 2024

Journal Articles

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Blood (2024) 144 (Supplement 1): 3500.

https://doi.org/10.1182/blood-2024-199776

Published: 2024

Journal Articles

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Roman M. Shapiro, Haesook T. Kim, William H Terral, Vincent T. Ho, Mahasweta Gooptu, Rizwan Romee, Christopher J. Gibson, Amar H. Kelkar, Corey S. Cutler, Joseph H. Antin, Katie Maurer, Catherine J. Wu, Robert Zeiser, Jerome Ritz, Robert J. Soiffer, Sarah Nikiforow, John Koreth

Blood (2024) 144 (Supplement 1): 4833.

https://doi.org/10.1182/blood-2024-194102

Published: 2024

Journal Articles

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Blood (2024) 144 (Supplement 1): 1027.

https://doi.org/10.1182/blood-2024-202676

Published: 2024

Journal Articles

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Jessica S. Little, Kyle Hebert, Donna S. Neuberg, Sarah Nikiforow, Mahasweta Gooptu, Roman M. Shapiro, John Koreth, Joseph H. Antin, Corey S. Cutler, Robert J. Soiffer, Jerome Ritz, Rizwan Romee, Vincent T. Ho, Nicolas C Issa, Lindsey R. Baden, Remy Dulery, Susan E Prockop

Blood (2024) 144 (Supplement 1): 4885.

https://doi.org/10.1182/blood-2024-205169

Published: 2024

Journal Articles

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Blood (2024) 144 (Supplement 1): 4938.

https://doi.org/10.1182/blood-2024-209087

Published: 2024

Journal Articles

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Blood (2024) 144 (Supplement 1): 4866.

https://doi.org/10.1182/blood-2024-205070

Published: 2024

Journal Articles

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Blood (2024) 144 (11): 1153–1167.

https://doi.org/10.1182/blood.2024024104

Published: 2024

Includes: Supplemental data

Journal Articles

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

Blood (2023) 142 (Supplement 1): 2105.

https://doi.org/10.1182/blood-2023-180224

Published: 2023

Journal Articles

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

Sarah Nikiforow, Mitchell Horwitz, John M. McCarty, Anum Abbas, James M. Coghill, Jenny Stanton, Julie Ma, Spyridoula Vasileiou, Sarah Gilmore, Bhagirathbhai Dholaria, Rabi Hanna, Randy Taplitz, Rajat Bansal

Blood (2023) 142 (Supplement 1): 6889.

https://doi.org/10.1182/blood-2023-189708

Published: 2023

Journal Articles

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

Blood (2023) 142 (Supplement 1): 6850.

https://doi.org/10.1182/blood-2023-178362

Published: 2023

Journal Articles

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Shuntaro Ikegawa, Adam S. Sperling, Michela Ansuinelli, Sarah Nikiforow, David Quinn, Dexiu Bu, Jennifer Mataraza, David Pearson, Lawrence Rispoli, Marc A Credi, Nina Orwitz, Yohei Arihara, Rao Prabhala, Lakshmi Bhavani Potluri, Carol Reynolds, Serena De Vita, Nikhil C Munshi, Jerome Ritz

Blood (2023) 142 (Supplement 1): 3469.

https://doi.org/10.1182/blood-2023-177721

Published: 2023

Journal Articles

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

Blood (2023) 142 (Supplement 1): 2537.

https://doi.org/10.1182/blood-2023-188829

Published: 2023

Journal Articles

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Blood (2023) 142 (Supplement 1): 2246.

https://doi.org/10.1182/blood-2023-185315

Published: 2023

Journal Articles

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Blood (2023) 142 (Supplement 1): 3618.

https://doi.org/10.1182/blood-2023-185220

Published: 2023

Journal Articles

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Blood (2023) 141 (24): 2932–2943.

https://doi.org/10.1182/blood.2022019107

Published: 2023

Includes: Supplemental data

NARROW

Updated Clinical Results: A Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab Plus Chemotherapy

Impact of Consolidative Cellular Therapy with DLI or Second Transplant in Patients with AML Who Achieve Complete Remission Following Post-Transplant Relapse

Effects of GvHD Prophylaxis with Post-Transplant Cyclophosphamide on Immune Reconstitution and TCR Repertoire after Haploidentical and HLA-Matched Transplantation Compared to Prophylaxis with Calcineurin Inhibitor Plus Methotrexate in HLA-Matched Transplantation

Prolonged Persistence and Functional Activity of Anti-BCMA CAR-T Durcabtagene Autoleucel (PHE885) Manufactured Using the T-Charge™ Platform

Heterogeneity of PD-1 + regulatory T Cells after Low-Dose IL-2 Therapy for Patients with Chronic Graft-Versus-Host Disease

BK Virus Reactivation and Disease after Allogeneic Hematopoietic-Cell Transplantation: A Natural History Study

Induction of Graft-Versus-Leukemia Effect with Treg-Depleted DLI Plus Ipilimumab for Myeloid Disease Relapse after HLA-Matched Transplant

Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma

Early CMV Viral Load Burden Predicts Late Clinically Significant CMV Infections in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Redefining Clinical Response Criteria in Myelodysplastic Syndromes to Better Forecast Post-Transplant Outcomes

Expression of HLA-B*35 Is Associated with an Increased Risk of CMV Viremia and Clinically Significant CMV Infection in Patients Receiving Ptcy-Based Hematopoietic Cell Transplantation

Phase 1 study of CAR-37 T cells in patients with relapsed or refractory CD37 + lymphoid malignancies

Expansion, Persistence, and Characteristics of Autologous, Bhv-1100 Armored Memory-like NK Cells Infused Prior to Autologous Stem Cell Transplant in MRD+ Multiple Myeloma Patients: A First-in-Human Trial

ALVR106, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Treatment of Respiratory Viral Infections: Results from a Phase 1, First-in-Human, Dose-Ranging Trial

CTLA-4 Blockade Results in the Enrichment of Proliferative CD56 dim CD16 + NK Cells Following Infusion of Haploidentical Donor Memory-like Natural Killer Cells Plus IL-15 Superagonist in a Phase 1 Trial

T-Charge™ Manufacturing of the Anti-BCMA CAR-T, Durcabtagene Autoleucel (PHE885), Promotes Expansion and Persistence of CAR-T Cells with High TCR Repertoire Diversity

Treatments and Outcomes of Lymphoma-Associated Hyperinflammation- a Report from the HLH in Adults Working Group for the Histiocyte Society

A Simple Prediction Model of Outcomes after Allogeneic Hematopoietic Stem Cell Transplant (HCT) in Myelodysplastic Syndromes Using HCT-Comorbidity Index, Cytogenetic Risk, and Platelet Count

Post Allogeneic Stem Cell Transplant Outcomes Following Response to Hypomethylating Agent Therapy in Myelodysplastic Syndromes Are Predicted By Persistent International Prognostic Scoring System-Molecular Risk

Phase 2 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only